Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis

Tuesday, November 24, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

Contacts:

Cephalon:

Media:

Investor Relations:

Sheryl Williams

Chip Merritt

610-738-6493 (office)

610-738-6376 (office)

610-457-5257 (cell)

[email protected]

[email protected]

Ception:

Media: Mike Beyer - Sam Brown Inc.

773-463-4211 (office)

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store